B
Bull
Bull · 25%MLTX
$48.66
Scenario price
$10.140
-0.263 (-2.59%)At close
Loading chart…
- High
- 10.650
- Open
- 10.300
- VWAP
- 10.27
- Volume
- 1.77M
- Mkt Cap
- 2.62B
- Low
- 10.005
- Amount
- 18.20M
- EV/EBITDA, TTM
- 0.00
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
AI analysis of MoonLake Immunotherapeutics (MLTX)
HoldMoonLake Immunotherapeutics is currently not a strong buy due to its high volatility and recent price decline, despite positive catalysts. The current price is $10.82, with a 5-day change of -5.17% and an RSI of 29.259 indicating oversold conditions. The company has a significant cash position of $537 million, which supports ongoing operations and clinical trials, but it also reported a substantial net loss of $69.7 million in Q1 2026, highlighting financial risks.
Valuation Metrics
The current forward P/E ratio for MoonLake Immunotherapeutics (MLTX) is 0.00, compared to its 5-year average forward P/E of -20.01.
Alphio AI Price Scenarios for MLTX
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding MLTX
Events Timeline
News
9.009-11stocktwitsMoonLake Plans FDA Filing for Sonelokimab Approval
9.508-10stocktwitsMoonLake Reports Positive Phase 3 Results and Narrower Q2 Loss
8.508-03stocktwitsMoonLake Immunotherapeutics Investor Day Highlights
8.507-13stocktwitsMerck's Key Drug Faces Patent Cliff Ahead
5.007-03FoolCFO Sells 39,120 Shares of MoonLake Immunotherapeutics
MLTX FAQ — answered by Alphio AI
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
MoonLake Immunotherapeutics is currently not a strong buy due to its high volatility and recent price decline, despite positive catalysts. The current price is $10.82, with a 5-day change of -5.17% and an RSI of 29.259 indicating oversold conditions. The company has a significant cash position of $537 million, which supports ongoing operations and clinical trials, but it also reported a substantial net loss of $69.7 million in Q1 2026, highlighting financial risks.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.